Tertomotide (hydrochloride)

Tertomotide (GV1001) hydrochloride is peptide vaccine consists a 16-aa human telomerase reverse transcriptase (hTERT) sequence. Tertomotide hydrochloride shows neuroprotective. Tertomotide hydrochloride has the potential for the research of Alzheimer's disease[1][2][3].

Product Specifications

CAS Number

[922174-60-5]

Product Name Alternative

GV-1001 (hydrochloride)

UNSPSC

12352005

Target

Telomerase

Related Pathways

Cell Cycle/DNA Damage

Field of Research

Neurological Disease

Smiles

O=C([C@H]1N(CCC1)C([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@@H](N)CCC(O)=O)=O)=O)=O)N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N3[C@@H](CCC3)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.Cl

Molecular Formula

C85H147ClN26O21

Molecular Weight

1904.69

References & Citations

[1]Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs. 2009 May;18 (5) :687-94.|[2]Koh SH, et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021 Mar 26;13 (1) :66.|[3]Park HH, et al. Novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiol Aging. 2014 Jun;35 (6) :1255-74.